Proteologix’s antibody PX128 is ready to enter early-stage development for moderate to severe atopic dermatitis, commonly referred to as eczema, and moderate to severe asthma.
Trending
- World not listening to us, laments Kenyan climate scientist at COP29
- Sokoto NUJ urges govt to address food security amid looming shortages
- High cost of transportation affecting food distribution – Expert
- Why diabetes-related amputations are high in Nigeria – EMSON
- More funding needed for research to boost local drugs production – Expert
- Vitamin D supplements may lower BP in older adults with obesity
- QNET unveils products to combat 5G radiation
- Food inflation: Experts seek review of FG’s agriculture policies
